STAT3 and colorectal carcinoma: Along this line, DHME appears as a potential candidate to be included in 5-FU-based CRC chemotherapeutic regimens to potentiate 5-FU’s therapeutic efficacy by impairing STAT3-elicited 5-FU resistance.